Dementia is no longer a specialist subset of residential care. It is the majority profile of the UK care home population. An estimated 70 to 80 per cent of all people living in care homes in England have dementia or severe memory problems. The total number of people living with dementia in the UK reached 982,000 in 2024, projected to exceed one million by 2030 and reach 1.6 million by 2050.

The Alzheimer’s Society estimates the annual cost of dementia to the UK economy at £42 billion in 2024, rising to £90 billion by 2040. For care providers, these are not background statistics. They describe the population your service already supports, the commissioning environment you are operating within, and the standard of specialist provision commissioners will increasingly expect to see evidenced in every tender you submit.

The Scale of Need in England

There are 7,504 care homes registered with CQC to provide services to older people with dementia in England, with approximately 340,000 potentially available beds. The quality of those beds varies significantly: the proportion rated Good or Outstanding by ICB area ranges from 52.3 per cent to 89.1 per cent, meaning that in the worst-performing areas, nearly half of all dementia care home beds are rated below Good. 

That gap is not simply a quality failure. It is a commissioning risk that local authorities and ICBs are actively working to address, including through the frameworks and spot contract decisions you are bidding for.

Key facts on the dementia population in England:

• By December 2024, formal diagnoses for people aged 65 and over reached a record high of 483,000.
• 97 per cent of all formal dementia diagnoses are in people aged 65 and over.
• Women account for 62 per cent of all cases.
• Approximately 70,000 people in England have young-onset dementia, developing before the age of 65.
• An estimated one third of people in England and Northern Ireland living with dementia have not received a formal diagnosis.
• 169,500 people with a formal dementia diagnosis are living in care homes, representing 34 per cent of all people diagnosed.

The undiagnosed proportion matters directly for providers. Residents may arrive with complex cognitive needs that no care plan has been built around. Providers with robust assessment and admission pathways, including tools that identify undiagnosed dementia at the point of admission, are better placed to respond safely from the outset and to evidence that proactive approach in tender submissions.

Who Is Entering Care Homes in 2026

The profile of people entering care homes is more complex than at any previous point. The NHS and social care system has progressively extended support at home, which means the threshold for care home admission has risen. People are arriving later in their dementia journey, with more co-existing health conditions, and with needs that require skilled clinical input from day one. This is a structural shift, not a temporary trend.

CQC data shows that homes where the majority of residents have dementia experience more than double the serious injury notifications compared with homes with lower dementia prevalence. The range of dementia conditions presents different challenges at different stages:

• Early-stage dementia can often be managed in a standard residential home with well-trained staff and a structured, stimulating environment.
• Moderate dementia typically requires dedicated dementia environments: secure outdoor spaces, wayfinding design, sensory rooms, structured daily activity programmes, and a staffing model that allows for consistent key worker relationships.
• Advanced dementia requires nursing-level input alongside specialist dementia care, covering swallowing difficulties, complex falls risk, behaviours that challenge, pressure area care, continence management, and end-of-life needs simultaneously, often in the same person on the same shift.

Funding Routes for Dementia Care in 2026

Families and commissioners accessing dementia care home placements can draw on several funding routes, each with different eligibility criteria, contribution requirements, and administrative pathways. Providers who understand these routes, and who can explain them clearly to families and commissioners, demonstrate the kind of operational sophistication that distinguishes high-scoring bids from adequate ones.

The main funding routes in 2026 are:

• NHS Continuing Healthcare (CHC): for people whose primary need arises from a health condition. Not means-tested. The ICB funds the full cost of the placement. Dementia alone does not automatically confer eligibility; the assessment is based on the nature, intensity, complexity, and unpredictability of care needs.
• NHS-Funded Nursing Care (FNC): for nursing home residents who are not eligible for CHC but require registered nursing input. Worth £254.06 per week at the standard rate or £349.50 at the higher rate in England for 2025/26. Not means-tested.
• Local authority means-tested funding: for people whose capital is below the upper threshold of £23,250 in England (2025/26). The lower threshold is £14,250, below which no capital contribution is required. The planned £100,000 cap on care costs was scrapped by the Labour government.
• Private self-funding: approximately 50 per cent of residential and nursing placements in England are privately funded. Average costs for residential dementia care in 2026 are approximately £1,375 per week and £1,585 per week for nursing dementia care.

Workforce, CQC Ratings, and the Evidence

The NIHR-funded MiCareHQ research programme analysed 5,555 care homes over three years and produced findings that every provider and commissioner should understand:

• A 10 per cent increase in the average hourly wage of care staff was associated with a 7 per cent higher probability of a Good or Outstanding CQC rating.
• Each additional percentage point of dementia-trained staff increased the probability of a Good or Outstanding rating by 1 per cent.
• Residents in Good or Outstanding homes experienced a 12 per cent improvement in social care-related quality of life compared with residents in lower-rated homes, specifically among those with the highest dependency.
• Homes that were short-staffed or struggling to retain staff consistently received lower ratings regardless of the quality of their written policies and procedures.

Investment in pay and dementia-specific training is a quality driver, a regulatory driver, and a commissioning driver. Cognitive Stimulation Therapy is the only non-pharmacological dementia intervention recommended by both NICE and the World Health Organization.

 It requires trained and confident staff to deliver consistently. Homes that embed structured evidence-based interventions into their dementia care model, rather than relying on ad hoc activities, are better positioned in both CQC inspections and competitive tenders.

What Commissioners Are Looking For

Commissioners awarding dementia care contracts are not looking for general statements of intent. They are looking for specific, evidenced answers to specific questions, and they read enough bids to know instantly whether the organisation behind the response has operational depth or is producing a document for the sake of compliance.

Commissioners typically probe the following:

• The provider’s model of person-centred dementia care and how it is operationalised on night shifts and weekends, not just in policy documents and during the day.
• The proportion of staff holding a dementia-specific qualification and when it was last updated, including whether Oliver McGowan Mandatory Training has been completed across the workforce.
• How the home manages and records behaviours that challenge, including what structured, non-pharmacological alternatives to medication are in place and how their effectiveness is reviewed.
• How residents’ life histories, cultural backgrounds, religious beliefs, dietary preferences, and individual communication styles are embedded into daily care, not just recorded in an admission document.
• Outcomes data: falls rates, avoidable hospital admissions, end-of-life quality indicators, resident and family satisfaction, and wellbeing measures collected using validated tools.
• Partnership arrangements: relationships with GP surgeries, community mental health teams, dementia advisory services, and specialist clinical input.

See also: Adult Social Services in the UK and NHS Mental Health Services in 2026

Conclusion

Dementia is the defining challenge of the care home sector in 2026. Commissioners expect providers who genuinely understand it: its clinical complexity, its workforce demands, its funding architecture, and its implications for outcomes. AssuredBID helps you translate what you do into written evidence that scores. We have supported providers bidding for dementia care frameworks across local authority and ICB commissioning, and we know what commissioners are looking for.